The ALS Association
Based in
United States
Sources: ror.org
Founded
Founded
1 Jan 1985
Sources: ror.org
Trials
Collaborator, Phase 2, Active, not recruiting, 41 people, 7 Jan 2020
Collaborator, Phase 2, Completed, 22 people, 12 Jun 2015
Collaborator, Phase 2, Completed, 31 people, 24 Jun 2013
Collaborator, Phase 2/3, Terminated, 84 people, 7 Jan 2009
Collaborator, Phase 2, Completed, 42 people, 11 Dec 2006
Collaborator, Phase 2, Completed, 86 people, 24 Jul 2006
Awards made
US$1m, 20 Aug 2026
High-throughput imaging screen to restore TDP-43 localization in aged neurons, 26-SGP-764, 2025–2026, 1 Feb 2025
High-throughput imaging screen to restore TDP-43 localization in aged neurons, 26-SGP-764, 50k, 2025–2026, 1 Feb 2025
Identification of ALS risk factors leading to CHIP-related Epi-age acceleration, 24-SGP-700, 2023–2024, 1 Oct 2023
Identification of ALS risk factors leading to CHIP-related Epi-age acceleration, 24-SGP-700, 2023–2024, 1 Oct 2023
Identification of ALS risk factors leading to CHIP-related Epi-age acceleration, 24-SGP-700, 50k, 2023–2024, Lead, 1 Oct 2023
[RESUBMISSION] Determining Changes in RNA and Protein Metabolism in ALS iMNs, 23-PDF-639, 2022–2024, 1 Dec 2022
[RESUBMISSION] Determining Changes in RNA and Protein Metabolism in ALS iMNs, 23-PDF-639, 2022–2024, 1 Dec 2022
[RESUBMISSION] Determining Changes in RNA and Protein Metabolism in ALS iMNs, 23-PDF-639, 2022–2024, 1 Dec 2022
[RESUBMISSION] Determining Changes in RNA and Protein Metabolism in ALS iMNs, 23-PDF-639, 150k, 2022–2024, Lead, 1 Dec 2022
Safety & therapeutic potential of metformin for C9orf72 ALS, 23-TC-644, 2022–2024, 1 Dec 2022
Safety & therapeutic potential of metformin for C9orf72 ALS, 23-TC-644, 500k, 2022–2024, 1 Dec 2022
Sources: mitochonpharma.com, firstatomtx.com, news.google.com, openalex.org
Funded papers
Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome
23‐PPG‐674‐2, 1 Sept 2026
Sources: api.crossref.org